Work in the lab was supported by postdoctoral fellowship grant to Dr. Anjali Nandal, and Exploratory grant from Maryland Stem Cell Research Fund to BT (TEDCO).

1. Reprogramming Protocol
<ol>
	<li>Generation of human iPSC from primary human pancreatic cells
	<ol>
		<li>Coat a 6-well plate with 1.5 mg/mL cold collagen and allow it to gel at 37 &#176;C for 1 h.</li>
		<li>Plate early passage human primary pancreatic cells in Prigrow III medium (~1 - 1.5 &#215; 105 cells) on a collagen coated 6-well plate on day -2 to achieve approximately 2.5 &#215; 105 cells or at least 60% confluency per well on the day of transduction (day 0). For the first study, plate at least 2 - 3 wells to get one well with desired confluency on day 0. Use at least one well as a control to count the cells.</li>
		<li>On the day of transduction (day 0), warm 1 mL of Prigrow III medium in a water bath for each well to be transduced. Harvest the cells from one control well in 1 mL of 10% FBS medium using 1 mL of trypsin/EDTA for 5 min or till the cells detach to perform a cell count. To make 10% FBS medium, add DMEM, 10% FBS, 1% L-Glutamine, 1% Sodium Pyruvate and 1% non-essential amino acids.</li>
		<li>Count and check the viability of the cells using the cell counter and calculate the volume of each virus needed to reach the target based on the cell number and virus titer. Use multiplicity of infection (MOI) of KOS = 5, hc-Myc = 5 and hKlf4 = 3 for the pancreatic cells.</li>
		<li>Thaw one set of Sendai vector tubes in the -80 &#176;C storage on ice and carefully add the calculated volumes of each of the three Sendai vector tubes to 1 mL of Prigrow III medium, pre-warmed to 37 &#176;C. Pipette gently to mix the solution. One well in a 6-well plate is enough for transducing with Sendai viral vectors to generate reprogrammed cells.</li>
		<li>Aspirate the Prigrow III medium from the cells, and slowly add the reprogramming virus mixture to the wells containing the cells. Incubate the cells overnight in a 37 &#176;C incubator with a humidified atmosphere of 5% CO2.</li>
		<li>Carefully discard the virus mixture on cells and replace with fresh Prigrow III medium the next day, 24 h after transduction. Culture the cells for 5 d and change the medium every alternate day.</li>
		<li>On day 5, prepare MEFs on 0.1% gelatin pre-coated 10 cm culture dishes (1.3 x106 cells/dish). Grow MEFs in T175 flasks till day 4 and then on day 5, expose the cells to 6,000 rads from a &#947;-radiation source before seeding the cells13 or use the commercial MEF source.</li>
		<li>On day 6, use 1 mL of cell detachment solution for 10 min to detach the transduced cells, plate all of them on MEF dishes in Prigrow III medium with rock inhibitor (5 mM stock, 10 &#181;M final) and incubate overnight in a 37 &#176;C incubator with a humidified atmosphere of 5% CO2.</li>
		<li>Change the Prigrow III medium to hESC medium the next day. For making 500 mL of hESC medium, add DMEM/F-12, 20% (v/v) knockout serum replacement (KOSR), 5 ng/mL bFGF; 1 mM l-glutamine; 100 &#181;M nonessential amino acids and 100 &#181;M 2-mercaptoethanol. Change the medium gently every day now.</li>
		<li>Observe the plates regularly for the emergence of cell clumps or colonies indicative of reprogrammed cells. The transformed cells form clonal aggregates with cobblestone morphology and big nucleus and nucleoli. Mark the probable &#39;iPSC&#39; colonies and check them regularly for growth.</li>
		<li>Almost four weeks after transduction as colonies are ready for picking or transfer, prepare 24-well MEF plates by plating 1.3 x 106 cells/gelatin pre-coated plate as before for the transfer of single colonies.
		<ol>
			<li>Prepare matrix membrane (e.g., Matrigel) by aliquoting it based on the dilution factor on the certificate of analysis. Add one aliquot to 25 mL of DMEM/F-12 to coat four 6-well plates (1 mL/well) and incubate at room temperature (RT) for at least 1 h before use. Manually pick 12-24 colonies by using a sterile pipette-tip to aspirate them and transfer onto MEF plates in 500 &#181;L of hESC medium.</li>
			<li>Aspirate the media in the well to gently disrupt or break apart the colonies. Also pick 24-48 colonies on matrix membrane coated 24-well plates. For the membrane coated plates, use mTeSR1 (supplemented with 10 &#181;M rock inhibitor) for 24 h and change every day. Within 6-10 d of picking colonies, they are ready to be transferred to the new 24-well and/or 12-well&#160;membrane plates for clonal expansion.</li>
		</ol>
		</li>
		<li>If needed, detach the colonies on MEFs using 1 mg/mL collagenase for 20 min, wash twice with hESC/mTeSR1 and transfer to&#160;membrane coated 12- or 24-well plates. If there are enough robust colonies growing on the matrix membrane from step 1.1.12, freeze the colonies on MEFs using iPSC freezing media as per the manufacturer&#39;s guidelines.</li>
		<li>Detach the robust colonies plated on the membrane in step 1.1.12 using 500 &#181;L of dispase for 20 min and plate again on matrix membrane coated 12-well plates. Manually scrape off any differentiated cells or contaminating MEF feeder cells to enrich for pluripotent clones on the&#160;membrane.</li>
		<li>Expand the clones after 6-8 d by growing on&#160;membrane coated plates by dissociating with dispase solution as before and plating small cell aggregates on fresh&#160;membrane coated 6- or 12-well plate. Change mTeSR1 medium daily. Characterize the reprogrammed clones by alkaline phosphatase staining, immunostaining for pluripotency markers (OCT3/4 and NANOG), FACS analysis of pluripotent surface markers and differentiation assays. Grow and culture the clones on membrane-coated plates for all the assays including CRISPR editing as explained above unless other coating solution is specifically mentioned.</li>
	</ol>
	</li>
	<li>Characterization of Human iPSCs
	<ol>
		<li>Alkaline Phosphatase staining 
		NOTE: A commercial kit is used here. See the Materials Table.
		<ol>
			<li>Plate putative human iPSCs on 24-well plate and culture for 4-5 d with daily media change.</li>
			<li>To start the staining protocol, aspirate the culture medium and wash the cells with 1 mL of 1x PBS with 0.05% Tween 20 (PBST).</li>
			<li>Add 0.5 mL of fix solution in the kit on the cells and incubate at RT for 2 to 5 min. Aspirate the fix solution and then wash the fixed cells with PBST. Do not allow the wells to dry.</li>
			<li>Add 0.5 mL of freshly prepared AP Substrate Solution per well by mixing solution A, B and C. Incubate the cells in the dark (wrapped with foil or in a dark container) at room temperature for 5 to 15 min. 
			NOTE: Closely monitor the color change and stop the reaction when the color turns bright to avoid non-specific staining.</li>
			<li>Stop the reaction by aspirating the AP Substrate Solution and washing the wells twice with 2 mL of 1x PBS.</li>
			<li>Observe the colonies under the microscope and capture the images at 4X or 10X magnification using any bright field microscope with a camera.</li>
		</ol>
		</li>
		<li>Immunostaining
		<ol>
			<li>Plate human iPSCs in 24-well plate and culture for 4-5 d with daily media change.</li>
			<li>Wash cells once briefly with PBS and fix for 20 min with 4% paraformaldehyde (PFA) in PBS.</li>
			<li>Wash three times for 10 min (3x, 10 min) with PBS at RT.</li>
			<li>Saturate non-specific sites with 10% normal goat or donkey serum (NS, depending on the animal secondary antibody was raised in) in PBS for 40 min at RT. For only intracellular epitopes, include 0.3% TX-100 in PBS (TX/PBS) to permeabilize.</li>
			<li>Wash 3x5 min with PBS at RT.</li>
			<li>Dilute the OCT4, NANOG, TUJ1, NKX2-5 and SOX17 antibodies in a fresh solution of 5% NS in PBS and incubate for 2 h at RT or overnight at 4 &#176;C.</li>
			<li>Wash 3x for 5 min with PBS at RT.</li>
			<li>Dilute appropriate secondary Alexa Fluor 488 or 568 antibodies in 5% NS/PBS and incubate cells for 1 h at RT.</li>
			<li>Wash 3x for 5 min at RT.</li>
			<li>Incubate with DAPI in PBS for 10 min and wash 2x for 5 min at RT. Use a fluorescent microscope to take pictures.</li>
		</ol>
		</li>
		<li>Fluorescence-activated Cell Sorting (FACS)
		<ol>
			<li>Plate human iPSCs in a 6-well plate and culture till the colonies become 80% confluent (at least 105 cells /sample) with daily mTeSR1 medium change.</li>
			<li>On the day of the experiment, isolate the cells and dissociate to a single cell suspension as explained above in the protocol. Wash with 10% FBS medium.</li>
			<li>For surface markers, resuspend in 0.5-1 mL of 10% FBS medium and keep on ice.</li>
			<li>For intracellular markers, resuspend in 1 mL of 4% PFA/PBS and incubate for 10 min at room temperature. Wash with 10% FBS medium. Resuspend in 0.1% TX/PBS and incubate for 15 min on ice. Wash again with 10% FBS medium. Resuspend in 0.5-1 mL of 10% FBS medium and keep on ice.</li>
			<li>Add 50 &#181;L of the cell suspension to 50 &#181;L of 10% FBS medium containing recommended amount of TRA-1-60, TRA-1-81 or SSEA-4 antibodies and incubate for 30 min to 1 h.</li>
			<li>Wash twice with 10% FBS.</li>
			<li>Resuspend in 100 &#181;L of 10% FBS medium containing fluorescent secondary antibodies and incubate for 30 min. Wash twice with 10% FBS and resuspend in appropriate volume of 10% FBS. The live cells can be differentiated from dead cells by propidium iodide dye added at &#60;1 &#181;g/mL to estimate cell apoptosis during the process.</li>
		</ol>
		</li>
		<li>Tri-lineage differentiation
		<ol>
			<li>Seed two 6-well plates with 1.5-2 x 106 iPSCs/well in mTeSR1 medium with 10 &#181;M rock inhibitor.</li>
			<li>Allow the cells to grow for 2-3 d with daily mTeSR1 medium change until the wells are 80-90% confluent.</li>
			<li>For ectoderm induction, add neural induction medium (NIM) according to the manufacturer&#39;s instructions in 2-3 wells of the 6-well plates.</li>
			<li>Change the medium to RPMI containing 2% B27 supplement minus insulin and 12 &#181;M CHIR99021 for mesoderm induction in 2-3 wells of the plates14. Add only RPMI containing 2% B27 supplement minus insulin for the next 24 h. Add 5 &#181;M IWP4 to the RPMI medium with 2% B27 supplement minus insulin for the next 24 h. After 72 h, replace the media with RPMI containing 2% B27 supplement leading to the generation of beating cardiomyocytes in 2-3 d.</li>
			<li>For endoderm induction, change the medium in wells of the 6-well plates to MCDB 131 supplemented with 1.5 g/L sodium bicarbonate, 1x Glutamax, 10 mM glucose, 0.5% BSA, 100 ng/mL GDF8, and 5&#181;M of CHIR99021 for 24 h. Culture in the same medium without CHIR99021 for 2-3 d15.</li>
			<li>Follow the immunostaining protocol from step 2 for all the three lineages and check for the expression of relevant markers.</li>
		</ol>
		</li>
	</ol>
	</li>
</ol>
2. Genome Editing of Human iPSC Using CRISPR-Cas9
<ol>
	<li>Preparation of Cas9 protein and sgRNA
	<ol>
		<li>Aliquot Cas9 protein into microcentrifuge tubes in sterile conditions and store the aliquots by freezing the tubes at -80 &#176;C.</li>
		<li>Design two targeting guide RNAs per gene based on the software from MIT (http://www.genome-engineering.org/crispr/) or any other CRISPR guide design webtool. Target first or second exon of the gene (based on open reading frame) to generate knockouts. Choose the two guides so that they cut close together (~30-100 bp apart) and we can easily visualize the deletion using the same set of screening primers. Choose the guides from the software output on the basis of higher quality score and lower number of off-target sites. Design screening primers using the program primer blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Screening primers should be at least 100 bp away from the Cas9 cut sites and the PCR product size should preferably be between 400-700 bp for easier amplification by PCR.</li>
		<li>Design the two complementary sgRNA oligo DNAs (19-22 nucleotides in length depending on the guide sequence) with a Bsa1 cut site at each end. The oligo DNAs can be synthesized commercially and annealed to form double-strand DNA. For annealing, add 1 &#181;L each of 100 &#181;M guides, 25 &#181;L of annealing buffer (10 mM Tris, pH7.5-8.0, 50 mM NaCl, 1 mM EDTA) and 23 &#181;L of water. Incubate in a thermocycler programmed to start at 95 &#176;C for 2 min and then gradually cooling to 25 &#176;C over 45 min.</li>
		<li>Clone the 2 &#181;L of resulting fragment into a Bsa1 restriction enzyme digested 1 &#181;L of in-house T7 promoter pCR2.1 vector with a Cas9 binding site using T4 DNA ligase as per the manufacturer&#39;s protocol.</li>
		<li>Sequence the cloned DNA fragments and when fidelity is established, in vitro transcribe the clones using a T7 kit to generate single guide RNAs. Purify the sgRNAs with a commercial kit and elute in RNase-free water. Check the RNA concentration.</li>
	</ol>
	</li>
	<li>Transfection of hiPSCs
	<ol>
		<li>Culture hiPSCs in mTeSR1 medium as described above until the cells are 40-50% confluent.</li>
		<li>Two hours before nucleofection, replace the medium with 2 mL of prewarmed mTeSR1 medium containing 10 &#181;M rock inhibitor.</li>
		<li>One hour later, prepare destination wells for nucleofected cells by aspirating&#160;membrane, prepared as above, from 12-well plate and replacing with prewarmed 1 mL of mTeSR1 medium with 10 &#181;M rock inhibitor. Keep at 37 &#176;C for incubation.</li>
		<li>Prepare nucleofection master mix (scale appropriately depending on the samples) for each sample by adding 16.4 &#181;L of P3 primary cell supplement; 3.6 &#181;L of Supplement 1 from the nucleofector kit; 0.5 &#181;g of Cas9 protein and 0.5 &#181;g of each sgRNA in 22 &#181;L per reaction volume. pMAX GFP vector was also nucleofected as per the manufacturer&#39;s recommendations in cells to roughly estimate the efficiency of iPSC transfection.</li>
		<li>Wash each well with 2 mL of RT PBS after aspirating the medium containing rock inhibitor from the iPSC wells. Then aspirate PBS, add 1 mL of cell detachment solution, and incubate the plate at 37 &#176;C for 10 min.</li>
		<li>Resuspend the cells in 3 mL of mTeSR1 medium and gently pipette up and down to generate a single-cell suspension. Transfer dissociated cells to a 15 mL centrifuge tube containing 5 mL mTeSR1 medium.</li>
		<li>Count cells with cell counter and calculate total volume required for 0.5 x 106 cells/transfection. Place desired quantity of cells in 15-mL centrifuge tube, centrifuge at 200 x g for 5 min at RT and aspirate supernatant.</li>
		<li>Resuspend each unit of 0.5 x 106 cells in 22 &#181;L of the transfection master mix prepared in step 4. Quickly transfer cells into the central chamber of one well of a nucleocuvette strip. Place the strip into a nucleofector device and nucleofect cells using program CB150.</li>
		<li>After nucleofection, quickly add 80 &#181;L of prewarmed mTESR1 medium containing 10 &#181;M rock inhibitor to each well of the nucleofected cells. Gently mix by pipetting up and down.</li>
		<li>Gently transfer cells from the strip to wells of the&#160;membrane pre-coated 12-well plate containing mTeSR1 medium with rock inhibitor prepared in step 3.</li>
		<li>After 1 d, change to fresh mTeSR1 medium without rock inhibitor. Harvest cells 2-3 d after nucleofection for single-cell sorting.</li>
	</ol>
	</li>
	<li>Single-Cell Isolation of targeted hiPSCs
	<ol>
		<li>One day before the sorting, prepare 96-well MEF plates by seeding 2 x 106 cells/gelatin-coated plate in 10% FBS medium. Approximately 70-80% of the clones survive after nucleofection and 2-3 MEF plates can be prepared for each editing experiment.</li>
		<li>Following the overnight incubation, change the medium to hESC medium (as described previously) supplemented with 100 ng/mL bFGF, 1x SMC4 (inhibitors added to the media to enhance single cell viability), and 5 mg/mL fibronectin to promote adhesion.</li>
		<li>Replace the medium on the hiPSCs in the 12-well plate from mTeSR1 to mTeSR1 medium supplemented with 1x SMC4 for at least 2 h before single cell sorting.</li>
		<li>Aspirate the medium from hiPSCs and wash the cells gently with PBS. Add 500 &#181;L of cell detachment solution in each well and incubate at 37 &#176;C for 10 min after aspirating the PBS. Generate the single-cell suspension by adding 1 mL of mTeSR1 (unsupplemented) to each well and pipetting up and down gently several times.</li>
		<li>Place cell suspension in a 15-mL conical tube and centrifuge for 5 min at 200 x g at RT. Aspirate supernatant and resuspend the cells in 1 mL of mTeSR1.</li>
		<li>Sort the cells in single cells using a cell sorter with 100 mm nozzle under sterile conditions with one cell in the individual well of the 96-well plates prepared in step 1.</li>
		<li>Four days after sorting, colony formation should be apparent; at this point replace the culture medium with hESC medium supplemented with 1x SMC4.</li>
		<li>Eight days after sorting, replace medium with hESC medium and culture for 2 d.</li>
		<li>Detach the colonies using 1 mg/mL collagenase for 20 min and transfer them to 24-well membrane coated plates in mTeSR1 with rock inhibitor. Let the single-cell clones grow and extract their genomic DNA after duplicating or expanding them. Use gene specific primers to amplify the target DNA by PCR.</li>
		<li>Use fragment analyzer kit for initial screening of PCR amplified target genomic region of all clones by running them through the gel/dye mix as per the manufacturer&#39;s instructions. Estimate the resulting fragment size in the software PROSize by comparing it with the appropriate ladder, which is run with the samples. Sequence the expected &#39;edited&#39; clones and analyze sequencing data to confirm the editing or deletions.</li>
		<li>For differentiating monoallelic and biallelic clones, amplify the edited sequence with PCR and clone in pJET1.2 vector. Send at least 8-10 clones for sequencing and check the sequence to confirm editing in one or both alleles.</li>
		<li>Once successfully targeted iPSC clones have been identified through genotyping, examine to confirm that they have not lost pluripotency or gained chromosomal abnormalities through the process.</li>
	</ol>
	</li>
</ol>

<ol><li>Malik, N., Rao, M. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+review+of+the+methods+for+human+iPSC+derivation%5BTitle%5D)+AND+%22Methods+Mol.+Biol%22%5BJournal%5D)">A review of the methods for human iPSC derivation.</a> Methods Mol. Biol. 997, 23-33 (2013).</li>
<li>Yu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induced+pluripotent+stem+cell+lines+derived+from+human+somatic+cells%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Induced pluripotent stem cell lines derived from human somatic cells.</a> Science. 318, 1917-1920 (2007).</li>
<li>Takahashi, K., Yamanaka, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+pluripotent+stem+cells+from+mouse+embryonic+and+adult+fibroblast+cultures+by+defined+factors%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.</a> Cell. 126, 663-676 (2006).</li>
<li>Sommer, C. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induced+pluripotent+stem+cell+generation+using+a+single+lentiviral+stem+cell+cassette%5BTitle%5D)+AND+%22Stem+cells%22%5BJournal%5D)">Induced pluripotent stem cell generation using a single lentiviral stem cell cassette.</a> Stem cells. 27, 543-549 (2009).</li>
<li>Macarthur, C. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+human-induced+pluripotent+stem+cells+by+a+nonintegrating+RNA+Sendai+virus+vector+in+feeder-free+or+xeno-free+conditions%5BTitle%5D)+AND+%22Stem+cells+Int%22%5BJournal%5D)">Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.</a> Stem cells Int. , 564612(2012).</li>
<li>Li, H. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+cytoplasmic+RNA+vector+derived+from+nontransmissible+Sendai+virus+with+efficient+gene+transfer+and+expression%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression.</a> J Virol. 74, 6564-6569 (2000).</li>
<li>Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+induction+of+transgene-free+human+pluripotent+stem+cells+using+a+vector+based+on+Sendai+virus%2C+an+RNA+virus+that+does+not+integrate+into+the+host+genome%5BTitle%5D)+AND+%22Proc.+Jpn.+Acad.+Ser.+B%2C+PhysBiol.+Sci%22%5BJournal%5D)">Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome.</a> Proc. Jpn. Acad. Ser. B, PhysBiol. Sci. 85, 348-362 (2009).</li>
<li>Nakagawa, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+novel+efficient+feeder-free+culture+system+for+the+derivation+of+human+induced+pluripotent+stem+cells%5BTitle%5D)+AND+%22Sci.+Rep%22%5BJournal%5D)">A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.</a> Sci. Rep. 4, 3594(2014).</li>
<li>Hockemeyer, D., Jaenisch, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induced+Pluripotent+Stem+Cells+Meet+Genome+Editing%5BTitle%5D)+AND+%22Cell+stem+cell%22%5BJournal%5D)">Induced Pluripotent Stem Cells Meet Genome Editing.</a> Cell stem cell. 18, 573-586 (2016).</li>
<li>Komor, A. C., Badran, A. H., Liu, D. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Based+Technologies+for+the+Manipulation+of+Eukaryotic+Genomes%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.</a> Cell. 169, 559(2017).</li>
<li>Komor, A. C., Badran, A. H., Liu, D. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Based+Technologies+for+the+Manipulation+of+Eukaryotic+Genomes%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.</a> Cell. 168, 20-36 (2017).</li>
<li>Sander, J. D., Joung, J. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Cas+systems+for+editing%2C+regulating+and+targeting+genomes%5BTitle%5D)+AND+%22Nat.+Biotech%22%5BJournal%5D)">CRISPR-Cas systems for editing, regulating and targeting genomes.</a> Nat. Biotech. 32, 347-355 (2014).</li>
<li>McElroy, S. L., Reijo Pera, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preparation+of+mouse+embryonic+fibroblast+feeder+cells+for+human+embryonic+stem+cell+culture%5BTitle%5D)+AND+%22CSH+Protoc%22%5BJournal%5D)">Preparation of mouse embryonic fibroblast feeder cells for human embryonic stem cell culture.</a> CSH Protoc. 2008, (2008).</li>
<li>Lian, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Robust+cardiomyocyte+differentiation+from+human+pluripotent+stem+cells+via+temporal+modulation+of+canonical+Wnt+signaling%5BTitle%5D)+AND+%22Proc.+Natl.+Acad.+Sci.+U.S.A%22%5BJournal%5D)">Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.</a> Proc. Natl. Acad. Sci. U.S.A. 109, E1848-E1857 (2012).</li>
<li>Rezania, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reversal+of+diabetes+with+insulin-producing+cells+derived+in+vitro+from+human+pluripotent+stem+cells%5BTitle%5D)+AND+%22Nat.+Biotech%22%5BJournal%5D)">Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells.</a> Nat. Biotech. 32, 1121-1133 (2014).</li>
<li>Shi, Y., Inoue, H., Wu, J. C., Yamanaka, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induced+pluripotent+stem+cell+technology%3A+a+decade+of+progress%5BTitle%5D)+AND+%22Nat.+Rev.+Drug+Discov%22%5BJournal%5D)">Induced pluripotent stem cell technology: a decade of progress.</a> Nat. Rev. Drug Discov. 16, 115-130 (2017).</li>
<li>Wang, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Highly+efficient+CRISPR%2FHDR-mediated+knock-in+for+mouse+embryonic+stem+cells+and+zygotes%5BTitle%5D)+AND+%22BioTechniques%22%5BJournal%5D)">Highly efficient CRISPR/HDR-mediated knock-in for mouse embryonic stem cells and zygotes.</a> BioTechniques. 59, (2015).</li>
<li>Liang, X., Potter, J., Kumar, S., Ravinder, N., Chesnut, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enhanced+CRISPR%2FCas9-mediated+precise+genome+editing+by+improved+design+and+delivery+of+gRNA%2C+Cas9+nuclease%2C+and+donor+DNA%5BTitle%5D)+AND+%22J+Biotech%22%5BJournal%5D)">Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA.</a> J Biotech. 241, 136-146 (2017).</li>
</ol>

BT is a founding member of RenOVAte Biosciences Inc.

Reprogramming of human somatic cells to iPSCs has provided a major boost to the fields of basic biology research, personalized medicine, disease modeling, drug development and regenerative medicine16. Many current and widely used methods of human iPSC generation require the use of virus with the risk of integration into the host genome or episomal vectors with low reprogramming efficiency. Here, we present an efficient method for generating feeder-free iPSCs from human pancreatic cells with Sendai...

The reprogramming of human somatic cells to the pluripotent state by overexpression of reprogramming factors has revolutionized stem cell research with applications in disease modeling, regenerative medicine, and drug development. Several non-viral reprogramming methods are available for delivery of reprogramming factors and generating iPSCs, but the process is labor intensive and not very efficient1. The viral methods, though efficient, are associated with problems of virus integration and tumorigenicity2,3,4. In this manuscript, we report the use of cytoplasmic Sendai virus for delivering reprogramming factors and establishing footprint-free iPSC lines that lack integration of any viral vector sequences into their genomes5. Sendai virus is an RNA virus that is diluted out of cell cytoplasm ~10 passages after infection and produces reprogramming factors in abundance, leading to rapid and efficient reprogramming6,7. The established iPSCs can then be readily transitioned to feeder-free medium&#160;to avoid the use of mouse embryonic fibroblasts (MEFs) as feeder cells8.
In this publication, in addition to outlining the Sendai virus mediated reprogramming, we also describe an improved protocol for editing iPSCs, which has the potential to supply unlimited human cells with desired genetic modifications for research. We have used CRISPR/Cas9 technology for the modification of iPSCs, which is now being used for a wide range of applications including knock-ins and knockouts, large-scale genomic deletions, pooled library screening for gene discovery, genetic engineering of numerous model organisms, and gene therapy9,10,11. This technique involves the formation of complexes of Streptococcus pyogenes-derived Cas9 nuclease and 20-mer guide RNAs that achieve target recognition via base-pairing with genomic target sequence adjacent to 3&#39; nucleotide protospacer adjacent motif (PAM) sequence. The Cas9 nuclease induces a double stranded break ~3 nucleotides from the PAM site, which is subsequently repaired predominantly by non-homologous end joining (NHEJ) pathway leading to insertions or deletions in the open reading frame, and thereby functional knockout of genes12.
Our improved protocol includes the details for culture of human pancreatic cells, their reprogramming on mitotically inactivated mouse embryonic fibroblasts (MEFs) to achieve higher efficiency of reprogramming, subsequent adaptation to feeder-free culture on Matrigel, characterization of established iPSCs, CRISPR guided RNA design and preparation, delivery into iPSCs as RNP complexes, single cell sorting to generate clonal lines of edited iPSCs, easy screening and identification of edits, and characterization of single cell clones. Genomic deletions were efficiently generated in this study by the introduction of Cas9 protein and two CRISPR sgRNA RNP complexes to induce double stranded breaks (DSBs) and deletion of the intervening segment. This method capitalizes on the use of two guides for generating deletions in the open reading frame, high efficiency of NHEJ leading to low number of clones that need to be characterized, and easy preliminary screening of clones by the automated capillary electrophoresis unit, fragment analyzer. These effective genome editing methods to generate human stem cell-based disease models will soon become a standard and routine approach in any stem cell laboratory. Finally, precise genome editing will make it possible to go beyond stem cell disease modeling and potentially could help catalyze cell-based therapies.

<table><tbody><tr><td>Sendai viral vectors - CytoTune-iPS 2.0 Kit</td><td>Invitrogen</td><td>A16517</td><td>Thaw on ice; S No: 1</td></tr><tr><td>Trypsin EDTA</td><td>Gibco Life Tech</td><td>25300-054</td><td>0.05%, 100 ml; S No: 2</td></tr><tr><td>Rock inhibitor (Y-27632)</td><td>Milipore</td><td>SCM075</td><td>Use 10 &amp;mu;M; S No: 3</td></tr><tr><td>DMEM/F-12 medium</td><td>Invitrogen</td><td>11330-032</td><td>S No: 4</td></tr><tr><td>Serum replacement (KSR)</td><td>Gibco</td><td>10828028</td><td>S No: 5</td></tr><tr><td>DMEM</td><td>Invitrogen</td><td>11960069</td><td>1X; S No: 6</td></tr><tr><td>Fetal bovine serum</td><td>Thermo Scientific</td><td>SH30071.03</td><td>Aliquot; S No: 7</td></tr><tr><td>L-glutamine (Glutamax, 100X), liquid</td><td>Thermo Scientific</td><td>35050061</td><td>1/100; S No: 8</td></tr><tr><td>Non-Essential Amino Acids</td><td>Gibco</td><td>11140-050</td><td>1/100; S No: 9</td></tr><tr><td>2-Mercaptoethanol</td><td>Gibco</td><td>21985023</td><td>55 mM, 1/1,000; S No: 10</td></tr><tr><td>Hausser Hemacytometers</td><td>Hausser Scientific</td><td>02-671-54</td><td>S No: 11</td></tr><tr><td>0.1% Gelatin Solution</td><td>STEMCELL Technologies</td><td>7903</td><td>Incubate at 37&amp;ordm; C for 1 hour; S No: 12</td></tr><tr><td>SSEA-4 antibody</td><td>Santacruz</td><td>sc-21704</td><td>1/100; S No: 13</td></tr><tr><td>TRA-1-81 antibody</td><td>Cell Signaling</td><td>4745S</td><td>1/200; S No: 14</td></tr><tr><td>OCT4 antibody</td><td>Santa Cruz</td><td>sc-5279</td><td>1/1,000; S No: 15</td></tr><tr><td>Collagen I, Rat Tail</td><td>Life Technologies</td><td>A10483-01</td><td>Keep cold; S No: 16</td></tr><tr><td>Alexa Fluor fluorescent 488/ 568 (secondary antibodies)</td><td>Invitrogen</td><td>A21202/A10042</td><td>1/2,000; S No: 17</td></tr><tr><td>DPBS</td><td>Hyclone</td><td>SH30028LS</td><td>1X; S No: 18</td></tr><tr><td>100-mm tissue culture dish</td><td>Falcon</td><td>353003</td><td>S No: 20</td></tr><tr><td>96-well tissue culture plate</td><td>Falcon</td><td>353078</td><td>S No: 21</td></tr><tr><td>6-well tissue culture plate</td><td>Falcon</td><td>353046</td><td>S No: 22</td></tr><tr><td>Dissecting scope&amp;nbsp;</td><td>Nikon</td><td>SMZ745</td><td>S No: 23</td></tr><tr><td>Picking hood</td><td>NuAire</td><td>NU-301</td><td>S No: 24</td></tr><tr><td>15&amp;nbsp;ml Centrifuge Tube</td><td>Greiner Bio-One</td><td>188271</td><td>S No: 25</td></tr><tr><td>50&amp;nbsp;ml Centrifuge Tube</td><td>Greiner Bio-One</td><td>227261</td><td>S No: 26</td></tr><tr><td>Sodium pyruvate</td><td>Invitrogen</td><td>11360</td><td>S No: 28</td></tr><tr><td>&amp;beta;-mercaptoethanol</td><td>Sigma</td><td>M7522</td><td>S No: 29</td></tr><tr><td>Prigrow III medium</td><td>ABM</td><td>TM003</td><td>S No: 31</td></tr><tr><td>Countess&amp;trade; Cell Counter</td><td>Invitrogen</td><td>C10227</td><td>S No: 32</td></tr><tr><td>Faxitron X-ray system</td><td>Faxitron</td><td>CellRad</td><td>S No: 33</td></tr><tr><td>Accutase</td><td>Innovative cell Technologies</td><td>AT-104</td><td>S No: 34</td></tr><tr><td>Collagenase</td><td>Life Technologies</td><td>17104019</td><td>1mg/ml stock; S No: 35</td></tr><tr><td>Dispase</td><td>STEMCELL Technologies</td><td>7923</td><td>S No: 36</td></tr><tr><td>hESC qualified matrigel</td><td>BD Biosciences</td><td>354277</td><td>To dilute, use cold DMEM/F-12; S No: 37</td></tr><tr><td>bFGF</td><td>R &amp;amp; D</td><td>233-FB</td><td>Stock 10 ug/ml; S No: 38</td></tr><tr><td>Paraformaldehyde</td><td>EMS</td><td>15710</td><td>4% stock in PBS; S No: 39</td></tr><tr><td>TRA-1-60</td><td>Santa Cruz</td><td>sc-21705</td><td>1/100; S No: 40</td></tr><tr><td>NANOG</td><td>ReproCELL</td><td>RCAB0004P-F</td><td>1/100; S No: 41</td></tr><tr><td>Tween 20</td><td>Sigma</td><td>P9416-100ML</td><td>S No: 42</td></tr><tr><td>Alkaline Phosphatase kit</td><td>Stemgent</td><td>00-0055</td><td>S No: 43</td></tr><tr><td>Cas9 protein</td><td>PNA Bio</td><td>CP01-50</td><td>Thaw and aliquot; S No: 44</td></tr><tr><td>Goat or donkey serum</td><td>Sigma</td><td>D9663/G9023</td><td>S No: 45</td></tr><tr><td>Triton X-100</td><td>Sigma</td><td>X100-100ML</td><td>S No: 46</td></tr><tr><td>DAPI</td><td>Thermo Scientific</td><td>D1306</td><td>S No: 47</td></tr><tr><td>Tris</td><td>Sigma</td><td>9285-100ML</td><td>S No: 48</td></tr><tr><td>NaCL</td><td>Sigma</td><td>S7653-250G</td><td>S No: 49</td></tr><tr><td>EDTA</td><td>Sigma</td><td>BP2482-500</td><td>S No: 50</td></tr><tr><td>T4 DNA ligase</td><td>NEB</td><td>M0202T</td><td>S No: 51</td></tr><tr><td>Mega Shortscript T7 kit</td><td>Thermo Scientific</td><td>AM1354</td><td>S No: 52</td></tr><tr><td>Mega Clear kit</td><td>Thermo Scientific</td><td>AM1908</td><td>S No: 53</td></tr><tr><td>SMC4</td><td>BD Biosciences</td><td>354357</td><td>S No: 54</td></tr><tr><td>Fibronectin</td><td>STEMCELL Technologies</td><td>7159</td><td>S No: 55</td></tr><tr><td>CloneJET cloning kit</td><td>Thermo Scientific</td><td>K1232</td><td>S No: 56</td></tr><tr><td>Fragment analyzer&lt;sup&gt;TM&lt;/sup&gt;</td><td>Advanced Analytical</td><td></td><td>S No: 57</td></tr><tr><td>mTeSR1 medium kit</td><td>STEMCELL Technologies</td><td>5850</td><td>Warm to room temperature; S No: 58</td></tr><tr><td>Freezing medium mFreSR&amp;trade;</td><td>STEMCELL Technologies</td><td>5855</td><td>S No: 59</td></tr><tr><td>Freezing medium CryoStor&amp;reg;</td><td>STEMCELL Technologies</td><td>7930</td><td>S No: 60</td></tr><tr><td>MEFs</td><td>Globalstem</td><td>GSC-6301G</td><td>S No: 61</td></tr><tr><td>L-glutamine</td><td>Invitrogen</td><td>25030081</td><td>S No: 62</td></tr><tr><td>Human pancreatic cells</td><td>ABM</td><td>T0159</td><td>S No: 63</td></tr><tr><td>STEMdiff&amp;trade; Neural Induction Medium</td><td>Stemcell Technologies</td><td>5835</td><td>S No: 64</td></tr><tr><td>RPMI</td><td>Thermofisher</td><td>11875-093</td><td>S No: 65</td></tr><tr><td>2% B27-insulin</td><td>Thermofisher</td><td>A1895601</td><td>S No: 66</td></tr><tr><td>CHIR99021</td><td>Stemcell Technologies</td><td>72052</td><td>S No: 67</td></tr><tr><td>IWP4</td><td>Stemcell Technologies</td><td>72552</td><td>S No: 68</td></tr><tr><td>2% B27</td><td>Thermofisher</td><td>17504044</td><td>S No: 69</td></tr><tr><td>MCDB 131</td><td>Life Technologies</td><td>10372019</td><td>S No: 70</td></tr><tr><td>Sodium bicarbonate</td><td>Sigma-Aldrich</td><td>S8761-100ML</td><td>S No: 71</td></tr><tr><td>Glucose</td><td>Sigma-Aldrich</td><td>G8270-100G</td><td>S No: 72</td></tr><tr><td>BSA</td><td>Proliant</td><td>68700</td><td>S No: 73</td></tr><tr><td>GDF8</td><td>Pepro-Tech</td><td>120-00</td><td>S No: 74</td></tr><tr><td>TUJ1 antibody</td><td>EMD Milipore</td><td>AB9354</td><td>S No: 75</td></tr><tr><td>NKX2-5 antibody</td><td>Santa Cruz</td><td>Sc-14033</td><td>S No: 76</td></tr><tr><td>SOX17 antibody</td><td>R &amp;amp; D systems</td><td>AF1924</td><td>S No: 77</td></tr><tr><td>Propidium iodide</td><td>Thermo Scientific</td><td>P3566</td><td>S No: 78</td></tr><tr><td>Amaxa 4D-nucleofector&amp;trade;</td><td>Lonza</td><td>AAF-1002</td><td>S No: 79</td></tr><tr><td>FACSAria II (cell sorter)</td><td>BD biosciences</td><td>SORP UV</td><td>S No: 80</td></tr></tbody></table>

efficient generation and editing of feeder-free ipscs from human pancreatic cells using the crispr-cas9 system

Embryonic and induced pluripotent stem cells can self-renew and differentiate into multiple cell types of the body. The pluripotent cells are thus coveted for research in regenerative medicine and are currently in clinical trials for eye diseases, diabetes, heart diseases, and other disorders. The potential to differentiate into specialized cell types coupled with the recent advances in genome editing technologies including the CRISPR/Cas system have provided additional opportunities for tailoring the genome of iPSC for varied applications including disease modeling, gene therapy, and biasing pathways of differentiation, to name a few. Among the available editing technologies, the CRISPR/Cas9 from Streptococcus pyogenes has emerged as a tool of choice for site-specific editing of the eukaryotic genome. The CRISPRs are easily accessible, inexpensive, and highly efficient in engineering targeted edits. The system requires a Cas9 nuclease and a guide sequence (20-mer) specific to the genomic target abutting a 3-nucleotide &#34;NGG&#34; protospacer-adjacent-motif (PAM) for targeting Cas9 to the desired genomic locus, alongside a universal Cas9 binding tracer RNA (together called single guide RNA or sgRNA). Here we present a step-by-step protocol for efficient generation of feeder-independent and footprint-free iPSC and describe methodologies for genome editing of iPSC using the Cas9 ribonucleoprotein (RNP) complexes. The genome editing protocol is effective and can be easily multiplexed by pre-complexing sgRNAs for more than one target with the Cas9 protein and simultaneously delivering into the cells. Finally, we describe a simplified approach for identification and characterization of iPSCs with desired edits. Taken together, the outlined strategies are expected to streamline generation and editing of iPSC for manifold applications.

In this publication, we have followed a simple but efficient protocol for the generation of iPSC from human pancreatic cells using integration or footprint-free Sendai virus vectors. Figure 1A shows a schematic representation of this reprogramming protocol. The human pancreatic cells were purchased commercially, cultured in Prigrow III medium and transduced with Sendai virus as explained above. Transduced spindle shaped pancreatic cells did not show any morph...

Watch this Scientific Journal Video about Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System at JoVE.com

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

This protocol describes in detail the generation of footprint-free induced pluripotent stem cells (iPSCs) from human pancreatic cells in feeder-free conditions, followed by editing using CRISPR/Cas9 ribonucleoproteins and characterization of the modified single-cell clones.

Embryonic and induced pluripotent stem cells can self-renew and differentiate into multiple cell types of the body. The pluripotent cells are thus coveted ...

efficient-generation-editing-feeder-free-ipscs-from-human-pancreatic

Research

JoVE Journal

Bioengineering

10.0K Views.  University of Maryland. Dit protocol beschrijft in detail de generatie van voetafdruk-vrije geïnduceerde pluripotente stamcellen (iPSCs) van menselijke pancreatic cellen onder feeder-vrije, gevolgd door bewerken met behulp van CRISPR/Cas9 ribonucleoproteins en karakterisering van de gewijzigde eencellige klonen.

Video: Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Efficient Generation of hiPSC Neural Lineage Specific Knockin Reporters Using the CRISPR/Cas9 and Cas9 Double Nickase System

Gene targeting is a critical approach for characterizing gene functions in modern biomedical research. However, the efficiency of gene targeting in human cells has been low, which prevents the generation of human cell lines at a desired rate. The past two years have witnessed a rapid progression on improving efficiency of genetic manipulation by genome editing tools such as the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR-associated) system. This manuscript describes a protocol for generating lineage specific human induced pluripotent stem cell (hiPSC) reporters using CRISPR/Cas system assisted homologous recombination. Procedures for obtaining necessary components for making neural lineage reporter lines using the CRISPR/Cas system, focusing on construction of targeting vectors and single guide RNAs, are described. This protocol can be extended to platform establishment and mutation correction in hiPSCs.

Genome editing tools such as the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR-associated) system have greatly improved gene targeting efficiency in human induced pluripotent stem cells (hiPSCs). This manuscript describes a protocol for generating lineage specific hiPSC reporter using CRISPR/Cas system assisted homologous recombination.

Gene targeting is a critical approach for characterizing gene functions in modern biomedical research. However, the efficiency of gene targeting in human ...

Developmental Biology

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Interrogating gene function in self-renewing or differentiating human pluripotent stem cells (hPSCs) offers a valuable platform towards understanding human development and dissecting disease mechanisms in a dish. To capitalize on this potential application requires efficient genome-editing tools to generate hPSC mutants in disease-associated genes, as well as in vitro hPSC differentiation protocols to produce disease-relevant cell types that closely recapitulate their in vivo counterparts. An efficient genome-editing platform for hPSCs named iCRISPR has been developed through the TALEN-mediated targeting of a Cas9 expression cassette in the AAVS1 locus. Here, the protocols for the generation of inducible Cas9 hPSC lines using cells cultured in a chemically defined medium and a feeder-free condition are described. Detailed procedures for using the iCRISPR system for gene knockout or precise genetic alterations in hPSCs, either through non-homologous end joining (NHEJ) or via precise nucleotide alterations using a homology-directed repair (HDR) template, respectively, are included. These technical procedures include descriptions of the design, production, and transfection of CRISPR guide RNAs (gRNAs); the measurement of the CRISPR mutation rate by T7E1 or RFLP assays; and the establishment and validation of clonal mutant lines. Finally, we chronicle procedures for hPSC differentiation into glucose-responsive pancreatic &#946;-like cells by mimicking in vivo pancreatic embryonic development. Combining iCRISPR technology with directed hPSC differentiation enables the systematic examination of gene function to further our understanding of pancreatic development and diabetes disease mechanisms.

Protocols to generate hPSC mutant lines using the iCRISPR platform and to differentiate hPSCs into glucose-responsive &#946;-like cells are described. Combining genome editing technology with hPSC-directed differentiation provides a powerful platform for the systematic analysis of the role of lineage determinants in human development and disease progression.

Interrogating gene function in self-renewing or differentiating human pluripotent stem cells (hPSCs) offers a valuable platform towards understanding ...

Genetics

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

Genome-editing of human pluripotent stem cells (hPSCs) provides a genetically controlled and clinically relevant platform from which to understand human development and investigate the pathophysiology of disease. By employing site-specific nucleases (SSNs) for genome editing, the rapid derivation of new hPSC lines harboring specific genetic alterations in an otherwise isogenic setting becomes possible. Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 are the most commonly used SSNs. All of these nucleases function by introducing a double stranded DNA break at a specified site, thereby promoting precise gene editing at a genomic locus. SSN-meditated genome editing exploits two of the cell&#39;s endogenous DNA repair mechanisms, non-homologous end joining (NHEJ) and homology directed repair (HDR), to either introduce insertion/deletion mutations or alter the genome using a homologous repair template at the site of the double stranded break. Electroporation of hPSCs is an efficient means of transfecting SSNs and repair templates that incorporate transgenes such as fluorescent reporters and antibiotic resistance cassettes. After electroporation, it is possible to isolate only those hPSCs that incorporated the repair construct by selecting for antibiotic resistance. Mechanically separating hPSC colonies and confirming proper integration at the target site through genotyping allows for the isolation of correctly targeted and genetically homogeneous cell lines. The validity of this protocol is demonstrated here by using all three SSN platforms to incorporate EGFP and a puromycin resistance construct into the AAVS1 safe harbor locus in human pluripotent&#160;stem cells.

Genome editing of human pluripotent stem cells (hPSCs) can be done quickly and efficiently. Presented here is a robust experimental procedure to genetically engineer hPSCs as exemplified by editing the AAVS1 safe harbor locus to express EGFP and introduce antibiotic resistance.

Genome-editing of human pluripotent stem cells (hPSCs) provides a genetically controlled and clinically relevant platform from which to understand human ...

Endogenous Protein Tagging in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9

A protocol is presented for generating human induced pluripotent stem cells (hiPSCs) that express endogenous proteins fused to in-frame&#160;N- or C-terminal fluorescent tags. The prokaryotic CRISPR/Cas9 system (clustered regularly interspaced short palindromic repeats/CRISPR-associated 9) may be used to introduce large exogenous sequences into genomic loci via homology directed repair (HDR). To achieve the desired knock-in, this protocol employs the ribonucleoprotein (RNP)-based approach where wild type Streptococcus pyogenes Cas9 protein, synthetic 2-part guide RNA (gRNA), and a donor template plasmid are delivered to the cells via electroporation. Putatively edited cells expressing the fluorescently tagged proteins are enriched by fluorescence activated cell sorting (FACS). Clonal lines are then generated and can be analyzed for precise editing outcomes. By introducing the fluorescent tag at the genomic locus of the gene of interest, the resulting subcellular localization and dynamics of the fusion protein can be studied under endogenous regulatory control, a key improvement over conventional overexpression systems. The use of hiPSCs as a model system for gene tagging provides the opportunity to study the tagged proteins in diploid, nontransformed cells. Since hiPSCs can be differentiated into multiple cell types, this approach provides the opportunity to create and study tagged proteins in a variety of isogenic cellular contexts.

Described here is a protocol for tagging endogenously expressed proteins with fluorescent tags in human induced pluripotent stem cells using CRISPR/Cas9. Putatively edited cells are enriched by fluorescence activated cell sorting and clonal cell lines are generated.

A protocol is presented for generating human induced pluripotent stem cells (hiPSCs) that express endogenous proteins fused to in-frame&#160;N- or ...

Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors

Induced Pluripotent Stem Cells (iPSCs) hold great promise for disease modeling and regenerative therapies. We previously reported the use of Episomal Vectors (EV) to generate integration-free iPSCs from peripheral blood mononuclear cells (PB MNCs). The episomal vectors used are DNA plasmids incorporated with oriP and EBNA1 elements from the Epstein-Barr (EB) virus, which&#160;allow for replication and long-term retainment of plasmids in mammalian cells, respectively. With further optimization, thousands of iPSC colonies can be obtained from 1 mL of peripheral blood. Two critical factors for achieving high reprogramming efficiencies&#160;are: 1) the use of a 2A &#34;self-cleavage&#34; peptide to link OCT4 and SOX2, thus achieving equimolar expression of the two factors; 2) the use of two vectors to express MYC and KLF4 individually. Here we describe a step-by-step protocol for generating integration-free iPSCs from adult peripheral blood samples. The generated iPSCs are integration-free as residual episomal plasmids are undetectable after five passages. Although the reprogramming efficiency is comparable to that of Sendai Virus (SV) vectors, EV plasmids are considerably more economical than the commercially available SV vectors. This affordable EV reprogramming system holds potential for clinical applications in regenerative medicine and provides an approach for the direct reprogramming of PB MNCs to integration-free mesenchymal stem cells, neural stem cells, etc.

This protocol describes a detailed method for efficient generation of integration-free iPSCs from human adult peripheral blood cells. With the use of four oriP/EBNA-based episomal vectors to express the reprogramming factors, KLF4, MYC, BCL-XL, or OCT4 and SOX2, thousands of iPSC colonies can be obtained from 1 mL of peripheral blood.

Induced Pluripotent Stem Cells (iPSCs) hold great promise for disease modeling and regenerative therapies. We previously reported the use of Episomal ...

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Human pluripotent stem cells offer a powerful system to study gene function and model specific mutations relevant to disease. The generation of precise heterozygous genetic modifications is challenging due to CRISPR-CAS9 mediated indel formation in the second allele. Here, we demonstrate a protocol to help overcome this difficulty by using two repair templates in which only one expresses the desired sequence change, while both templates contain silent mutations to prevent re-cutting and indel formation. This methodology is most advantageous for gene editing coding regions of DNA to generate isogenic control and mutant human stem cell lines for studying human disease and biology. In addition, optimization of transfection and screening methodologies have been performed to reduce labor and cost of a gene editing experiment. Overall, this protocol is widely applicable to many genome editing projects utilizing the human pluripotent stem cell model.

This protocol provides a method to facilitate the generation of defined heterozygous or homozygous nucleotide changes using CRISPR-CAS9 in human pluripotent stem cells.

Human pluripotent stem cells offer a powerful system to study gene function and model specific mutations relevant to disease. The generation of precise ...

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Duchenne muscular dystrophy (DMD) is a severe progressive muscle disease caused by mutations in the dystrophin gene, which ultimately leads to the exhaustion of muscle progenitor cells. Clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) gene editing has the potential to restore the expression of the dystrophin gene. Autologous induced pluripotent stem cells (iPSCs)-derived muscle progenitor cells (MPC) can replenish the stem/progenitor cell pool, repair damage, and prevent further complications in DMD without causing an immune response. In this study, we introduce a combination of CRISPR/Cas9 and non-integrated iPSC technologies to obtain muscle progenitors with recovered dystrophin protein expression. Briefly, we use a non-integrating Sendai vector to establish an iPSC line from dermal fibroblasts of Dmdmdx mice. We then use the CRISPR/Cas9 deletion strategy to restore dystrophin expression through a non-homologous end joining of the reframed dystrophin gene. After PCR validation of exon23 depletion in three colonies from 94 picked iPSC colonies, we differentiate iPSC into MPC by doxycycline (Dox)-induced expression of MyoD, a key transcription factor playing a significant role in regulating muscle differentiation. Our results show the feasibility of using CRISPR/Cas9 deletion strategy to restore dystrophin expression in iPSC-derived MPC, which has significant potential for developing future therapies for the treatment of DMD.

Here, we present a Cas9-based exon23 deletion protocol to restore dystrophin expression in iPSC from Dmdmdx mouse-derived skin fibroblasts and directly differentiate iPSCs into myogenic progenitor cells (MPC) using the Tet-on MyoD activation system.

Duchenne muscular dystrophy (DMD) is a severe progressive muscle disease caused by mutations in the dystrophin gene, which ultimately leads to the ...

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

In order to investigate the events driving heart development and to determine the molecular mechanisms leading to myocardial diseases in humans, it is essential first to generate functional human cardiomyocytes (CMs). The use of these cells in drug discovery and toxicology studies would also be highly beneficial, allowing new pharmacological molecules for the treatment of cardiac disorders to be validated pre-clinically on cells of human origin. Of the possible sources of CMs, induced pluripotent stem (iPS) cells are among the most promising, as they can be derived directly from readily accessible patient tissue and possess an intrinsic capacity to give rise to all cell types of the body 1. Several methods have been proposed for differentiating iPS cells into CMs, ranging from the classical embryoid bodies (EBs) aggregation approach to chemically defined protocols 2,3. In this article we propose an EBs-based protocol and show how this method can be employed to efficiently generate functional CM-like cells from feeder-free iPS cells.

Pluripotent stem cells, either embryonic or induced pluripotent stem (iPS) cells, constitute a valuable source of human differentiated cells, including cardiomyocytes. Here, we will focus on cardiac induction of iPS cells, showing how to use them to obtain functional human cardiomyocytes through an embryoid bodies-based protocol.

In order to investigate the events driving heart development and to determine the molecular mechanisms leading to myocardial diseases in humans, it is ...

Biology

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

This manuscript illustrates a protocol for efficiently creating integration-free human induced pluripotent stem cells (iPSCs) from peripheral blood using episomal plasmids and histone deacetylase (HDAC) inhibitors. The advantages of this approach include: (1) the use of a minimal amount of peripheral blood as a source material; (2) nonintegrating reprogramming vectors; (3) a cost effective method for generating vector free iPSCs; (4) a single transfection; and (5) the use of small molecules to facilitate epigenetic reprogramming. Briefly, peripheral blood mononuclear cells (PBMCs) are isolated from routine phlebotomy samples and then cultured in defined growth factors to yield a highly proliferative erythrocyte progenitor cell population that is remarkably amenable to reprogramming. Nonintegrating, nontransmissible episomal plasmids expressing OCT4, SOX2, KLF4, MYCL, LIN28A, and a p53 short hairpin (sh)RNA are introduced into the derived erythroblasts via a single nucleofection. Cotransfection of an episome that expresses enhanced green fluorescent protein (eGFP) allows for easy identification of transfected cells. A separate replication-deficient plasmid expressing Epstein-Barr nuclear antigen 1 (EBNA1) is also added to the reaction mixture for increased expression of episomal proteins. Transfected cells are then plated onto a layer of irradiated mouse embryonic fibroblasts (iMEFs) for continued reprogramming. As soon as iPSC-like colonies appear at about twelve days after nucleofection, HDAC inhibitors are added to the medium to facilitate epigenetic remodeling. We have found that the inclusion of HDAC inhibitors routinely increases the generation of fully reprogrammed iPSC colonies by 2 fold. Once iPSC colonies exhibit typical human embryonic stem cell (hESC) morphology, they are gently transferred to individual iMEF-coated tissue culture plates for continued growth and expansion.

Here we describe a protocol for generating human induced pluripotent stem cells from peripheral blood using an episome based reprogramming strategy and histone deacetylase inhibitors.

This manuscript illustrates a protocol for efficiently creating integration-free human induced pluripotent stem cells (iPSCs) from peripheral blood using ...

Differentiating Human Pluripotent Stem Cells into Pancreatic β-Cells

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells

Human pluripotent stem cells (hPSCs) can differentiate into any kind of cell, making them an excellent alternative source of human pancreatic &#946;-cells. hPSCs can either be embryonic stem cells (hESCs) derived from the blastocyst or induced pluripotent cells (hiPSCs) generated directly from somatic cells using a reprogramming process. Here a video-based protocol is presented to outline the optimal culture and passage conditions for hPSCs, prior to their differentiation and subsequent generation of insulin-producing pancreatic cells. This methodology follows the six-stage process for &#946;-cell directed differentiation, wherein hPSCs differentiate into definitive endoderm (DE), primitive gut tube, posterior foregut fate, pancreatic progenitors, pancreatic endocrine progenitors, and ultimately pancreatic &#946;-cells. It is noteworthy that this differentiation methodology takes a period of 27 days to generate human pancreatic &#946;-cells. The potential of insulin secretion was evaluated through two experiments, which included immunostaining and glucose-stimulated insulin secretion.

Author Spotlight: Advancements and Challenges in &#946;-Cells Differentiation from Pluripotent Stem Cells

This article presents a protocol for directed differentiation and functional analysis of &#946;-cell like cells. We describe optimal culture conditions and passages for human pluripotent stem cells before generating insulin-producing pancreatic cells. The six-stage differentiation progresses from definitive endoderm formation to functional &#946;-cell like cells secreting insulin in response to glucose.

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Samenvatting

Meer video's verkennen